Second Locoregional Recurrence Predicts Survival Among Patients With Sarcoma

Share this content:
Researchers reported outcomes for patients who underwent a second resection after disease recurrence.
Researchers reported outcomes for patients who underwent a second resection after disease recurrence.
The following article features coverage from the Connective Tissue Oncology Society (CTOS) in Maui, Hawaii. Click here to read more of Cancer Therapy Advisor's conference coverage.

Post–second resection local recurrence is highly predictive of disease outcomes among patients with retroperitoneal sarcoma, according to an oral presentation at the Connective Tissue Oncology Society (CTOS) 2017 Annual Meeting.1

After first recurrence with retroperitoneal sarcoma, further relapse is common, and the relationship between resection and patient outcomes is not well-defined. For this study, researchers reported outcomes for patients who underwent a second resection after disease recurrence. The primary endpoints were disease-free survival and overall survival.

Of 603 included patients, 312 were female and 291 were male, the median age was 56 years, the median tumor size at initial resection was 18 cm, and the median tumor size at second resection was 11 cm.

After a median follow-up of 119 months after initial surgery and 75 months after second surgery, the 5-year disease-free survival was 23% and the 5-year overall survival was 58%. Age at first surgery, sarcoma subtype excluding well-differentiated liposarcoma, higher disease grade, incomplete second surgery, and greater number of organs resected at first surgery were predictive of survival outcomes.

The risk of local recurrence continued post–second resection and was predictive of disease outcomes. Distant recurrence was rarer.

The institution of first surgery was not, however, predictive of any outcomes post–second surgery.

Using these data, the authors created a nomogram for predicting 6-year overall survival. The data will be included in the “Sarculator,” a platform for predicting sarcoma survival, which is under development.

Read more of Cancer Therapy Advisor's coverage of the Connective Tissue Oncology Society (CTOS) by visiting the conference page.

Reference

  1. Raut CP, Callegaro D, Barretta F, et al. Predicting survival in patients (pts) undergoing resection for locoregionally recurrent retroperitoneal sarcoma (LRRPS): a study and nomogram from the Transatlantic Retroperitoneal Sarcoma Working Group (TARPSWG). Oral presentation at: Connective Tissue Oncology Society (CTOS) 2017 Annual Meeting. November 8-11, 2017; Maui, Hawaii.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs